Search jobs
Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS
JERSEY CITY, N.J., Dec. 22, 2020 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis (ALS). The studies are sponsored by Mitsubishi Tanabe Pharma Development America, Inc. (MTDA).
"As a company, we strive to always put patients first in our efforts to understand this debilitating disease," said Atsushi Fujimoto, President, MTPA. "We hope this extension study will help provide important information to the ALS community."